Prescriber acceptance rate of pharmacists’ recommendations

Jonathan F. Doellner*, Rick W. Dettloff, Susan DeVuyst-Miller, Katie L. Wenstrom

Objectives: To determine the prescriber acceptance rates of pharmacists’ recommendations, specifically related to 2 Medicare Part D Star ratings: appropriate use of high-risk medications (HRMs) in elderly patients and use of statins for primary prevention in patients with diabetes. The secondary objective was to assess factors associated with prescriber acceptance.

Design: Retrospective cohort.

Setting and participants: Medicare Part D beneficiaries at a regional grocery store chain pharmacy in Michigan from January 2014 to October 2015.

Main outcome measures: Prescriber acceptance rate of recommendations related to HRM use or treatment with a statin in patients with diabetes.

Results: Data were collected and analyzed for 200 patients, of which 100 were recommended to discontinue an HRM (HRM group) and 100 were recommended statin therapy owing to diabetes (statin group). Out of the 200 pharmacist-initiated recommendations, 100 were directed to a prescriber and therefore included in the calculation of prescriber acceptance. Overall, 35.0% of those recommendations were accepted, with individual group rates of 58.9% (23/39) and 19.7% (12/61) in the HRM group and statin group, respectively. Patients who were prescribed a statin for primary prevention of cardiovascular events were more likely to have concurrent dyslipidemia.

Conclusion: The prescriber acceptance rates observed in this study were similar to those reported in published literature. The results of this study might suggest that prescribers and patients with diabetes may be reluctant to initiate statin therapy for primary prevention without a concurrent diagnosis of dyslipidemia. Although further research is required, strategies to optimize communication and augment patient education may be useful to increase prescriber as well as patient acceptance of recommendations made by community pharmacists.

© 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

The United States health care system spends nearly $300 billion each year on morbidity and mortality resulting from medication misuse, with more than $177 billion due to avoidable adverse drug events.1,2 Efforts to reduce this deficit include improving coordination of care, increasing medication adherence, and reducing hospital readmissions. Community pharmacists, some of the most accessible health care professionals, are helping to bridge the gaps in care and achieve desired health outcomes with the use of medication therapy management (MTM).3

Medication therapy management services are primarily designed to improve medication adherence and ensure safe, effective, and appropriate use of medications through a patient-centered, interdisciplinary, and evidence-based approach.2,4 Indeed, MTM services provided by pharmacists are effective in managing high-risk populations, improving patient-centered outcomes, and reducing overall health care costs.5,7 Payors have recognized the value of pharmacists in improving the quality of patient care and have made pharmacist-led comprehensive medication reviews (CMRs) a covered service for Medicare Part D beneficiaries.8

As of 2016, the Centers for Medicare and Medicaid Services (CMS) include MTM program completion rate for CMRs as a quality measure for Medicare Part D Star ratings. Quality measures affected by pharmacists include appropriate use of high-risk medications in patients 65 years of age and older, ensuring that patients with diabetes and hypertension are

Disclosure: The authors declare no conflicts of interest or financial interests in any product or service mentioned in this article, including grants, employment, gifts, stock holdings, honoraria, consultancies, expert testimonies, patents, and/or royalties.

Previous presentation: American Pharmacists Association Annual Meeting, Baltimore, MD, March 5, 2016; and Annual Great Lakes Pharmacy Resident Conference, Purdue University, West Lafayette, IN, April 27, 2016.

* Correspondence: Jonathan F. Doellner, PharmD, 533 Leland Place, Lansing, MI 48917.
E-mail address: doellnj@gmail.com (J.F. Doellner).
find MTM to be beneficial for their patients and value such services offered by pharmacists, prescriber acceptance rates of pharmacists’ recommendations remain fairly low, at around 50% and ranging from 30% to 60%.2,6,10-19 In a nationwide survey of third-party payers of MTM, prescriber resistance was one of the most frequently reported barriers to MTM services.7,15 Overcoming this resistance is critical for pharmacists’ interventions to be effective and MTM to be successful.

Pharmacists’ time and resources must be allocated appropriately to be efficient in conducting CMRs. Third-party payers focus on high-risk patients who are most likely to experience poor clinical outcomes based on chronic disease states and number of chronic medications and would therefore benefit most from a CMR with a pharmacist.1,15,19 Identifying the patient populations for whom prescribers are more likely to accept recommendations by pharmacists may assist MTM providers in working with prescribers to optimize medication regimens and improve health outcomes.2,3,15,19

Knowledge of which patient factors are associated with prescriber acceptance of pharmacist-initiated recommendations may be useful to further refine patient eligibility criteria and pharmacist efficiency while also better understanding how to increase prescriber response and approval of recommendations intended to improve patient outcomes.

Methods

Study design and population

This was a retrospective cohort study of Medicare Part D beneficiaries in Michigan who may or may not have received a CMR at a regional grocery store chain pharmacy from January 1, 2014, to October 31, 2015. The study received approval from Ferris State University’s Institutional Review Board, and it was determined that the study meets Federal Regulations Expedited-Category 2E.

Patients were included in the study if they were 65 years of age or older and had been identified for 1 of the 2 Star ratings. After determining eligible participants, we randomly selected 100 patients from each population (statin group and HRM group), which were examined separately. If a patient was deemed to be ineligible after further review, he or she was excluded from the study and replaced by the next patient on the list of eligible claims. Common reasons for exclusion were mostly the patient lacking an OutcomesMTM profile at the time of data collection, inappropriate claim initially included...
دریافت فوری 
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات